Swarajya Logo
Swarajya Logo
Politics States Economy Society Business Culture Infra Defence World Books Ideas Science Technology Heritage Archives Legal Movies Sports
  • Our Views
    Politics States Economy Society Business Culture Infra Defence World Books Ideas Science Technology Heritage Archives Legal Movies Sports
  • Magazine
  • Store

About Swarajya

Swarajya is a publication by Kovai Media Private Limited.

Swarajya - a big tent for liberal right of centre discourse that reaches out, engages and caters to the new India.

editor@swarajyamag.com

Useful Links

  • About Us
  • Subscriptions Support
  • Editorial Philosophy
  • Press Kit
  • Privacy Policy
  • Terms of Use
  • Code of Conduct
  • Plagiarism Policy
  • Refund & Cancellation Policy

Useful Links

  • About Us
  • Subscriptions Support
  • Editorial Philosophy
  • Press Kit
  • Privacy Policy
  • Terms of Use
  • Code of Conduct
  • Plagiarism Policy
  • Refund & Cancellation Policy

Participate

  • Contact Us
  • Write for us
  • Style Guide
  • Jobs

Stay Connected

  • Artboard 2 Copy 6Created with Sketch.
    Artboard 2 Copy 10Created with Sketch.
    Artboard 2 Copy 7Created with Sketch.
    Artboard 2 Copy 9Created with Sketch.
  • Andriod Logo
  • IOS Logo

News Brief

Pfizer's Covid Pill To Be Produced In Many Countries Even As An Imminent Authorisation Is On The Way In US

Bhaswati Guha Majumder Thursday, November 18, 2021 2:32 pm IST
Pfizer anti-Covid pill. (Representative image)
Pfizer anti-Covid pill. (Representative image)
Pfizer anti-Covid pill. (Representative image)
  • If Pfizer receives FDA approval, this might revolutionise the fight against Covid-19 by allowing high-risk persons infected with the novel coronavirus to take an oral antiviral medicine at home rather than travelling to the hospital.
  • American pharma giant Pfizer, which developed mRNA Covid-19 vaccine along with German firm BioNTech, has submitted its application to the Food and Drug Administration (FDA) for emergency authorisation of its five-day antiviral pill regimen, Paxlovid.

    This is the second such drug looking for approval, as the fellow drugmaker, Merck asked the federal agency to grant emergency authorisation for its Covid pill, called molnupiravir, last month.

    If Pfizer receives FDA approval, this might revolutionise the fight against Covid-19 by allowing high-risk persons infected with the novel coronavirus to take an oral antiviral medicine at home rather than travelling to the hospital.

    According to Pfizer, when treated within three days of the onset of symptoms, the combination of Paxlovid and an HIV drug called ritonavir reduced hospitalisation and death by 89 per cent in adults 18 and older at a higher risk of developing severe Covid-19.

    According to reports, Pfizer's application to FDA came just a few days after the company disclosed that the drug regimen's clinical trial had been ended early due to strong evidence that it worked.

    But this is not the first time that a clinical trial is halted before the completion to benefit more people. Earlier, an independent group of medical professionals overseeing the trials of Merck’s anti-Covid pill molnupiravir, suggested that it be terminated early because the preliminary results were so promising.

    However, Pfizer has started producing and packaging the medicine in plants in Ireland, Germany and Italy, with 180,000 tablet packs expected to be accessible by the end of the year and 50 million by 2022.

    Covid Pill And 95 Developing Nations

    Meanwhile, the company has agreed to make and sell its experimental Covid-19 therapy tablet in 95 developing countries including India — where, as per the latest reports, the Subject Expert Committee is expected to make a decision on recommending approval to molnupiravir soon.

    The agreement with the non-profit Medicines Patent Pool, which is supported by the United Nations, may make the medication available to 53 per cent of the world's population.

    As reported, while Covid remains a World Health Organization-designated public health emergency, Pfizer will not collect royalties for the sales in low-income countries and has stated that it will waive royalties in all those nations participating in the deal.

    According to Charles Gore, head of the Medicines Patent Pool, the licence is crucial since "this oral drug is particularly well-suited for low- and middle-income countries and could play a critical role in saving lives", reported BBC.

    While in this case, the majority of the countries are from Africa and Asia continent, nations that have seen severe outbreaks, including Brazil, China, Russia, Argentina and Thailand, are not included in the agreement. This move has been criticised by an international medical non-governmental organisation, called Doctors Without Borders.

    According to the organisation, it was "disheartened" that the deal doesn't make the medication available everywhere in the world. The group's legal policy adviser Yuanqiong Hu said: "The world knows by now that access to Covid-19 medical tools need to be guaranteed for everyone, everywhere, if we really want to control this pandemic."

    However, The Washington Post reported that the American government has also pre-purchased 3.1 million molnupiravir treatment courses for $2.2 billion. Merck anticipates that 10 million treatment courses will be available by the end of the year and has also licensed its medicine to the Medicines Patent Pool.

    Additionally, the report noted that this week, the Joe Biden administration is expected to announce that it has obtained 10 million courses of Pfizer anti-Covid treatment.

    So now it is believed that these two anti-Covid treatment options could be game-changers in the fight to halt the pandemic.

    Tags
    Health
    Food and Drug Administration (FDA)
    Prescription Drugs
    Pfizer
    coronavirus treatment
    Molnupiravir
    Merck antiviral pill
    Pfizer Covid pill
    Paxlovid
    Covid treatment pill

    Comments ↓

    An Appeal...


     

    Dear Reader,

     

    As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

     

    Our business model is you and your subscription.  And in challenging times like these, we need your support now more than ever.

     

    We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

     

    Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

    Get Swarajya in your inbox.


    Magazine


    Swarajya Magazine Cover Image
    Merchandise

    Merchandise


      Politics

      Mahua Moitra Received Luxury Items, Travel And Holiday Expenses: What Ethics Committee Report Says In Cash-For-Query Case

      Mahua Moitra Received Luxury Items, Travel And Holiday Expenses: What Ethics Committee Report Says In Cash-For-Query Case

      Nishtha Anushree
      7m

      Not Like The Old Times: BJP's Feeble Victory In Rajasthan (Part II)

      Venu Gopal Narayanan
      14m

      "Shashi Tharoor Should Be In Jail": After Mahua Moitra, TMC MP's "Jilted Ex" Targets Congress MP, Accuses Of Molestation

      Nishtha Anushree
      44m

      Economy

      Enough Of Big Bang Reforms? No Major Announcements In Next Budget, "Wait Till July 2024", Says Nirmala Sitharaman

      Enough Of Big Bang Reforms? No Major Announcements In Next Budget, "Wait Till July 2024", Says Nirmala Sitharaman

      Nishtha Anushree
      22h

      ₹58,378 Crores! Govt Set To Open Taps On Additional Welfare Spending With 2024 In Mind

      Swarajya News Staff
      1d

      India Anticipated To Be Fastest Growing In Next Three Years, Set to Become Third Largest Economy By 2030: S&P

      Nishtha Anushree
      3d

      Defence

      Indian Army Sets Sight On Future: Developing AI And Cybersecurity Tech; Can Now Interpret Enemy's Electronic Order Of Battle

      Indian Army Sets Sight On Future: Developing AI And Cybersecurity Tech; Can Now Interpret Enemy's Electronic Order Of Battle

      Swarajya Staff
      3h

      Indian Air Force's C-17 Globemaster-III Transport Aircraft Successfully Drops DRDO-Developed Heavy Airdrop Platform

      Swarajya Staff
      4h

      India's Strategic Forces Command Conducts Training Launch Of Agni-1 Short Range Ballistic Missile

      Ujjwal Shrotryia
      18h

      World

      Maldives Skips Key Indian Ocean Security Meet With India And Other Neighbours, Opts For Chinese Forum Amidst Growing Tilt

      Maldives Skips Key Indian Ocean Security Meet With India And Other Neighbours, Opts For Chinese Forum Amidst Growing Tilt

      Swarajya Staff
      50m

      Azerbaijan President Accuses India And France Of Fuelling Armenia's Fire Of 'Revenge' For Loss In Nagorno-Karabakh War

      Swarajya Staff
      1h

      PM Modi Can't Be Forced Into Acting Against National Interests Of India: Putin

      Swarajya Staff
      6h

      Culture

      ‘Garba Of Gujarat’ Declared As Intangible Heritage By UNESCO

      ‘Garba Of Gujarat’ Declared As Intangible Heritage By UNESCO

      Arun Kumar Das
      1d

      Gujarat's Garba Is Now In List Of UNESCO Intangible Cultural Heritage of Humanity

      Swarajya News Staff
      1d

      'Celebrate At Home': Champat Rai Of Ram Janambhoomi Trust Urges Hindus Not To Visit Ayodhya On 22 January

      Bhuvan Krishna
      3d
      States

      infrastructure


      Amit Mishra
      1

      Kochi Metro Phase II: 11.2 Km Network To Be Ready By November 2026, AIIB Loan Approval Awaited

      2 Mins Read
      Arun Kumar Das
      2

      Make-In-India Initiatives Are Driving Growth In Manufacturing Sector, Says Ashwini Vaishnaw

      3 Mins Read
      Arun Kumar Das
      3

      Further Delay In Mumbai-Ahmedabad Bullet Train Project As Japanese Consortium Seeks More Time To Submit Rolling Stock Bids

      2 Mins Read
      Amit Mishra
      4

      Gujarat Government Partners With AAI For Building 11 New Airports, PM Modi's Hometown Also Under Consideration

      2 Mins Read